About Caladrius

Caladrius Biosciences, Inc. is a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases.

News

June 4, 2019
Caladrius Biosciences Completes Enrollment in Phase 2 ESCaPE-CMD Trial for Coronary Microvascular Dysfunction

May 9, 2019
Caladrius Biosciences Reports 2019 First Quarter Financial Results and Provides Corporate Update

May 7, 2019
Caladrius Biosciences to Participate at the Upcoming May Conferences

Events

May 9, 2019
Caladrius Biosciences 1st Quarter 2019 Financial Results and Business Update Conference Call

March 21, 2019
ARM’s Cell & Gene Therapy Investor Day

March 14, 2019
Caladrius Biosciences 4th Quarter 2018 Financial Results and Business Update Conference Call

Sign up to our e-mail list to receive Caladrius announcements.

Technologies & Capabilities

T Regulatory Cell Technology

T Regulatory Cell Technology

CD34 Cell Technology

CD34 Cell Technology